Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Non-comparative, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ceftolozane/Tazobactam (MK-7625A) in Pediatric Participants With Nosocomial Pneumonia
Conditions
Interventions
Ceftolozane/Tazobactam
Locations
24
United States
AdventHealth Orlando ( Site 1318)
Orlando, Florida, United States
Mayo Clinic in Rochester, Minnesota ( Site 1322)
Rochester, Minnesota, United States
Montefiore Medical Center [Bronx, NY] ( Site 1313)
New York, New York, United States
Sanford Children's Hospital ( Site 1301)
Sioux Falls, South Dakota, United States
West Virginia University ( Site 1310)
Morgantown, West Virginia, United States
Children's Wisconsin ( Site 1321)
Milwaukee, Wisconsin, United States
Start Date
April 17, 2020
Primary Completion Date
September 14, 2024
Completion Date
September 14, 2024
Last Updated
September 22, 2025
NCT06162455
NCT02413242
NCT01897792
NCT01796717
NCT00610324
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions